Want to see FR:ALTHE full AI Analyst Report?
Top Page
Theraclion SA
(ALTHE)
Select Model
Select Model
Rating:47Neutral
Price Target:
€0.60
▲(0.85% Upside)
Action:Reiterated
Date:07/10/26
The score is primarily constrained by weak financial performance—persistent losses, ongoing cash burn, and balance-sheet pressure from negative equity and meaningful debt. Technical indicators are relatively neutral with some longer-term support above key moving averages, but they do not outweigh the fundamental and valuation risks of a loss-making business.
Positive Factors
Focused HIFU product platform
Theraclion’s focus on imaging‑guided HIFU (Echopulse) is a durable strategic strength: it targets a clear clinical niche—non‑invasive treatment for benign conditions—providing differentiation versus conventional surgical or thermal therapies and supporting long‑term adoption as minimally invasive care expands.
Negative Factors
Structural unprofitability
Persistent gross, operating and net losses indicate the current cost and pricing model does not support profitability. Absent material margin expansion or cost restructuring, continuing losses will erode capital, limit reinvestment in commercialization, and require repeated external funding to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused HIFU product platform
Theraclion’s focus on imaging‑guided HIFU (Echopulse) is a durable strategic strength: it targets a clear clinical niche—non‑invasive treatment for benign conditions—providing differentiation versus conventional surgical or thermal therapies and supporting long‑term adoption as minimally invasive care expands.
Read all positive factors
Theraclion SA (ALTHE) vs. iShares MSCI France ETF (EWQ)
Market Cap
€46.94M
Dividend YieldN/A
Average Volume (3M)82.89K
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue Growth42.86%
EPS Growth13.93%
CountryFR
Employees36
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.10
Shares Outstanding73,368,710
10 Day Avg. Volume39,747
30 Day Avg. Volume82,891
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)-13.53
Price to Sales (P/S)29.53
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Theraclion SA Business Overview & Revenue Model
Company Description
Theraclion SA, established in 2004 and based in Malakoff, France, specializes in developing innovative echotherapy medical solutions. These treatments harness high-intensity focused ultrasound (HIFU) technology. Their offerings include SONOVEIN, a...
How the Company Makes Money
null...
Theraclion SA Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.19M | 830.00K | 1.82M | 1.24M | 1.48M |
| Gross Profit | -6.21M | -7.18M | -1.08M | -3.05M | -4.54M |
| EBITDA | -5.99M | -5.92M | -4.49M | -5.74M | -4.40M |
| Net Income | -5.69M | -5.76M | -3.68M | -4.96M | -3.76M |
Balance Sheet | |||||
| Total Assets | 12.51M | 11.47M | 18.66M | 13.94M | 11.83M |
| Cash, Cash Equivalents and Short-Term Investments | 3.38M | 4.17M | 7.82M | 2.52M | 2.49M |
| Total Debt | 5.09M | 1.30M | 1.95M | 2.51M | 2.39M |
| Total Liabilities | 15.10M | 11.47M | 13.01M | 13.40M | 13.10M |
| Stockholders Equity | -2.59M | -114.00 | 5.65M | 544.87K | -1.27M |
Cash Flow | |||||
| Free Cash Flow | -7.16M | -3.01M | -2.60M | -5.59M | -4.03M |
| Operating Cash Flow | -7.16M | -2.91M | -2.48M | -5.27M | -3.88M |
| Investing Cash Flow | -414.00K | -188.00K | -213.52K | -739.63K | -524.46K |
| Financing Cash Flow | 6.78M | -545.00K | 7.99M | 6.03M | 4.56M |
Theraclion SA Technical Analysis
Positive
0.59
Price Trends
0.66
Negative
0.60
Positive
0.61
Positive
Market Momentum
<0.01
Negative
54.44
Neutral
52.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTHE, the sentiment is Positive. The current price of 0.59 is below the 20-day moving average (MA) of 0.62, below the 50-day MA of 0.66, and below the 200-day MA of 0.61, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.44 is Neutral, neither overbought nor oversold. The STOCH value of 52.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALTHE.
Theraclion SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | €39.56M | -0.97 | -96.46% | ― | 0.87% | 46.31% | |
54 Neutral | €223.98M | -3.95 | 90.10% | ― | 1.79% | 15.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | €31.20M | 7.73 | -58.93% | ― | 7.43% | ― | |
47 Neutral | €46.94M | -6.01 | 222.05% | ― | 42.86% | 13.93% | |
46 Neutral | €23.05M | -5.57 | -21.61% | ― | 37.28% | 7.83% |
* Healthcare Sector Average
FR:ALTHE
Theraclion SA
0.66
>-0.01
-0.76%
FR:ALMKT
MAUNA KEA TECHNOLOGIES
0.16
0.05
49.52%
FR:ALNOV
Novacyt
0.51
0.04
9.62%
FR:ALDMS
Diagnostic Medical Systems
1.04
-0.39
-27.27%
FR:ALIKO
Ikonisys SA
1.52
0.00
0.00%
FR:ALMDT
Median Technologies
4.55
2.01
78.94%
Theraclion SA Corporate Events
Theraclion accelerates Sonovein rollout as China and U.S. strategies take shape
Jul 23, 2026
Theraclion reported that commercial momentum for its Sonovein varicose‑vein therapy platform is now visible across its sales cycle, signing seven new pay‑per‑use contracts in 2026 and installing four systems by mid‑year, ma...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.